Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

Discovery of Novel Histone Deacetylase 6 (HDAC6) Inhibitors with Enhanced Antitumor Immunity of Anti-PD-L1 Immunotherapy in Melanoma.

Authors:
Xiaopeng Peng Ling Li Jingxuan Chen Yichang Ren Jin Liu Ziwen Yu Hao Cao Jianjun Chen

J Med Chem 2022 02 19;65(3):2434-2457. Epub 2022 Jan 19.

School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 516000, China.

A series of 2-phenylthiazole analogues were designed and synthesized as potential histone deacetylase 6 (HDAC6) inhibitors based on compound (an HDAC6/tubulin dual inhibitor discovered by us recently) and CAY10603 (a known HDAC6 inhibitor). Among them, compound was the most potent HDAC6 inhibitor with an IC of 31 nM and excellent HDAC6 selectivity (SI = 338 for HDAC6 over HDAC3). also displayed high antiproliferative activity against various cancer cell lines including the HDACi-resistant YCC3/7 gastric cancer cells (IC = 0.16-2.31 μM), better than CAY10603. Further, (50 mg/kg) exhibited significant antitumor efficacy in a melanoma tumor model with a tumor growth inhibition (TGI) of 63% without apparent toxicity. Moreover, efficiently enhanced the antitumor immune response when combined with a small-molecule PD-L1 inhibitor, as demonstrated by the increased tumor-infiltrating lymphocytes and reduced PD-L1 expression levels. Taken together, the above results suggest that is a promising HDAC6 inhibitor deserving further investigation.

Download full-text PDF

 Source
http://dx.doi.org/10.1021/acs.jmedchem.1c01863DOI Listing
February 2022

Publication Analysis

Top Keywords

hdac6 inhibitor
12
enhanced antitumor
8
histone deacetylase
8
deacetylase hdac6
8
hdac6 inhibitors
8
hdac6
7
inhibitor
5
cancer cell
4
activity cancer
4
small-molecule pd-l1
4
deserving investigation
4
cell lines
4
discovery novel
4
lines including
4
combined small-molecule
4
including hdaci-resistant
4
antiproliferative activity
4
inhibitor demonstrated
4
pd-l1 inhibitor
4
high antiproliferative
4

Keyword Occurance

Similar Publications

HDAC Inhibition as Potential Therapeutic Strategy to Restore the Deregulated Immune Response in Severe COVID-19.

Authors:
Chiara Ripamonti Valeria Spadotto Pietro Pozzi Andrea Stevenazzi Barbara Vergani Mattia Marchini Giovanni Sandrone Emanuele Bonetti Luca Mazzarella Saverio Minucci Christian Steinkühler Gianluca Fossati

Front Immunol 2022 3;13:841716. Epub 2022 May 3.

New Drug Incubator Department, Italfarmaco Group, Cinisello Balsamo, Italy.

The COVID-19 pandemic has had a devastating impact worldwide and has been a great challenge for the scientific community. Vaccines against SARS-CoV-2 are now efficiently lessening COVID-19 mortality, although finding a cure for this infection is still a priority. An unbalanced immune response and the uncontrolled release of proinflammatory cytokines are features of COVID-19 pathophysiology and contribute to disease progression and worsening. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Macrophage migration inhibitory factor (MIF) acetylation protects neurons from ischemic injury.

Authors:
Jin-Xia Hu Wei-Jing Ma Li-Ying He Cong-Hui Zhang Cheng Zhang Yan Wang Chao-Nan Chen Da-Yong Shen Hui-Min Gao Rui-Ru Guo Qian-Qian Ning Xin-Chun Ye Gui-Yun Cui Lei Li

Cell Death Dis 2022 May 18;13(5):466. Epub 2022 May 18.

ShanghaiTech University, Shanghai, China.

Ischemia-induced neuronal death leads to serious lifelong neurological deficits in ischemic stroke patients. Histone deacetylase 6 (HDAC6) is a promising target for neuroprotection in many neurological disorders, including ischemic stroke. However, the mechanism by which HDAC6 inhibition protects neurons after ischemic stroke remains unclear. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

HDAC6 modulates myofibril stiffness and diastolic function of the heart.

Authors:
Ying-Hsi Lin Jennifer L Major Tim Liebner Zaynab Hourani Joshua G Travers Sara A Wennersten Korey R Haefner Maria A Cavasin Cortney E Wilson Mark Y Jeong Yu Han Michael Gotthardt Scott K Ferguson Amrut V Ambardekar Maggie Py Lam Chunaram Choudhary Henk L Granzier Kathleen C Woulfe Timothy A McKinsey

J Clin Invest 2022 May;132(10)

Department of Medicine, Division of Cardiology, and.

Passive stiffness of the heart is determined largely by extracellular matrix and titin, which functions as a molecular spring within sarcomeres. Titin stiffening is associated with the development of diastolic dysfunction (DD), while augmented titin compliance appears to impair systolic performance in dilated cardiomyopathy. We found that myofibril stiffness was elevated in mice lacking histone deacetylase 6 (HDAC6). Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Azetidin-2-one-based small molecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism of action and impact of dual inhibition profile on cell viability.

Authors:
Stefano Federico Tuhina Khan Anna Fontana Simone Brogi Rosaria Benedetti Federica Sarno Gabriele Carullo Alex Pezzotta Akella Prasanth Saraswati Eugenia Passaro Luca Pozzetti Alessandro Papa Nicola Relitti Sandra Gemma Stefania Butini Anna Pistocchi Anna Ramunno Fabrizio Vincenzi Katia Varani Vanessa Tatangelo Laura Patrussi Cosima T Baldari Simona Saponara Beatrice Gorelli Stefania Lamponi Massimo Valoti Fulvio Saccoccia Marialaura Giannaccari Giovina Ruberti Daniel Herp

Eur J Med Chem 2022 May 1;238:114409. Epub 2022 May 1.

Institute of Pharmaceutical Sciences, Albert-Ludwigs-Universität Freiburg, 79104, Freiburg, Germany.

The search of new therapeutic tools for the treatment of cancer is being a challenge for medicinal chemists. Due to their role in different pathological conditions, histone deacetylase (HDAC) enzymes are considered valuable therapeutic targets. HDAC6 is a well-investigated HDAC-class IIb enzyme mainly characterized by a cytoplasmic localization; HDAC8 is an epigenetic eraser, unique HDAC-class I member that displays some aminoacidic similarity to HDAC6. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Identification of mercaptoacetamide-based HDAC6 inhibitors a lean inhibitor strategy: screening, synthesis, and biological evaluation.

Authors:
Silke Geurs Dorien Clarisse Freya Baele Jorick Franceus Tom Desmet Karolien De Bosscher Matthias D'hooghe

Chem Commun (Camb) 2022 May 24;58(42):6239-6242. Epub 2022 May 24.

SynBioC Research Group, Department of Green Chemistry and Technology, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, B-9000 Ghent, Belgium.

Non-selective inhibition of different histone deacetylase enzymes by hydroxamic acid-based drugs causes severe side effects when used as a (long-term) cancer treatment. In this work, we searched for a potent zinc-binding group able to replace the contested hydroxamic acid by employing a lean inhibitor strategy. This instructed the synthesis of a set of HDAC6-selective inhibitors containing the more desirable mercaptoacetamide moiety. Read More

View Article and Full-Text PDF
May 2022
Similar Publications
}